3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1/2
2
Phase 1
2
Status
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Lymphoma, Non-Hodgkin
2
Recurrence
1
Neoplasm Metastasis
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
B-Cell Malignancies
1
Interventions
Rituximab
56
Cyclophosphamide
39
fludarabine
23
fludarabine phosphate
18
Peripheral Blood Stem Cell Transplantation
17
Lenalidomide
14
Melphalan
13
Etoposide
12
venetoclax
11
Whole-Body Irradiation
11
Mycophenolic Acid
11
obinutuzumab
10
Vincristine
10
Prednisone
10
Bendamustine Hydrochloride
10
Doxorubicin
9
Cytarabine
9
Cyclosporine
9
Bortezomib
9
Filgrastim
8
pembrolizumab
7
Nivolumab
7
Gemcitabine
7
Busulfan
7
acalabrutinib
6
Tacrolimus
6
Interleukin-2
6
Dexamethasone
6
Carmustine
6
Alemtuzumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, Non-Hodgkin
×
parsaclisib
×
Clear all
NCT04661007
2026-05-18
J-MIND
Incyte Corporation
Phase 1/2
Active not recruiting
72 enrolled
NCT04809467
2026-02-04
topMIND
Incyte Corporation
Phase 1/2
Terminated
54 enrolled
23 charts